Colorectal Cancer Therapeutics Market size was over USD 22.36 billion in 2024 and is projected to reach USD 75.39 billion by 2037, witnessing around 9.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of colorectal cancer therapeutics is evaluated at USD 24.11 billion.
The growth of the market is primarily attributed to the rising prevalence of colorectal cancer across the globe, increasing awareness of the serious impacts of colorectal cancer, and growing diagnostic methods. For instance, nearly 2.3 million cases of colorectal cancer were diagnosed in 2020, making it the third most prevalent cancer type worldwide.
Further, systematic treatments include chemotherapy, targeted therapy, and immunotherapy. Rising awareness in people regarding cancer, and increasing count of colorectal cancer screenings are robustly driving the growth of the market. It is observed that every year, more than 16 million colonoscopies are conducted in the United States.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
9.8% |
Base Year Market Size (2024) |
USD 22.36 billion |
Forecast Year Market Size (2037) |
USD 75.39 billion |
Regional Scope |
|
Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Embolization, Surgery)
The global colorectal cancer therapeutics market is segmented and analyzed for demand and supply by therapy into targeted therapy, immunotherapy, chemotherapy, radiation therapy, embolization, surgery, and others. Out of these, the targeted therapy segment is projected to significantly grow over the forecast period on the back of its highly effective and lifesaving functions, and increasingly sophisticated therapeutics. For instance, chemotherapy sessions offer only around a 25% chance of success, whereas targeted therapy is close to 75% effective.
Our in-depth analysis of the global market includes the following segments:
By Therapy |
|
By Cancer Type |
|
By Application |
|
By End-User |
|
North America Market Forecast
The North America region colorectal cancer therapeutics market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The escalating incidences of colorectal cancer coupled with supportive government initiatives, rising healthcare expenditure, rising number of colon cancer, and increasing awareness among people regarding the screening of colorectal cancer. For instance, the third most prevalent cancer in the United States is colorectal cancer. Around 105,280 new cases of colon cancer and 45,760 new cases of rectal cancer are estimated to be diagnosed in 2022.
Novartis AG announced the promising clinical data for its investigational KRASG12C inhibitor JDQ443, an investigational selective, covalent, and orally bioavailable inhibitor at the annual meeting of the American Association for Cancer Research (AACR)
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?